Twist Bioscience: Q3 Earnings Insights

 

Shares of Twist Bioscience TWST remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share were down 22.39% year over year to ($0.82), which missed the estimate of ($0.75).

Revenue of $35,018,000 higher by 65.12% year over year, which beat the estimate of $32,270,000.

Guidance

The upcoming fiscal year's revenue expected to be between $129,000,000 and $132,000,000.

Details Of The Call

Date: Aug 06, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/d5a3xjnj

Price Action

52-week high: $214.07

52-week low: $53.81

Price action over last quarter: Up 6.32%

Company Profile

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!